Open AccessDihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?
Author(s) -
Vijay Patil,
Vanita Noronha,
Amit Joshi,
Saurabh Zanwar,
Anant Ramaswamy,
Supreeta Arya,
Abhishek Mahajan,
Atanu Bhattacharjee,
Kumar Prabhash
Publication year - 2016
Publication title -
south asian journal of cancer
Language(s) - English
Resource type - Journals
eISSN - 2278-4306
pISSN - 2278-330X
DOI - 10.4103/2278-330x.195338
Subject(s) - medicine , confidence interval , regimen , exact test , chemotherapy , incidence (geometry) , oncology , gastroenterology , dihydropyrimidine dehydrogenase , fluorouracil , docetaxel , surgery , physics , optics , thymidylate synthase
The docetaxel, 5-fluorouracil (5-FU), and cisplatin (TPF) regimen in India is associated with high percentages of Grade 3-4 toxicity. This analysis was planned to evaluate the incidence of dihydropyrimidine dehydrogenase (DPD) mutation in patients with severe gastrointestinal toxicity, to assess whether the mutation could be predicted by a set of clinical criteria and whether it has any impact on postneoadjuvant chemotherapy response.